Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PRPH's Cash to Debt is ranked higher than
99% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. PRPH: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PRPH' s 10-Year Cash to Debt Range
Min: 4.97  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.70
PRPH's Equity to Asset is ranked higher than
62% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. PRPH: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
PRPH' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.74 Max: 0.96
Current: 0.7
0.48
0.96
F-Score: 4
Z-Score: 2.70
M-Score: -4.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -30.85
PRPH's Operating margin (%) is ranked lower than
86% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.78 vs. PRPH: -30.85 )
Ranked among companies with meaningful Operating margin (%) only.
PRPH' s 10-Year Operating margin (%) Range
Min: -87.5  Med: -9.02 Max: 49.86
Current: -30.85
-87.5
49.86
Net-margin (%) -30.87
PRPH's Net-margin (%) is ranked lower than
86% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. PRPH: -30.87 )
Ranked among companies with meaningful Net-margin (%) only.
PRPH' s 10-Year Net-margin (%) Range
Min: -87.5  Med: -8.70 Max: 29.91
Current: -30.87
-87.5
29.91
ROE (%) -65.01
PRPH's ROE (%) is ranked lower than
89% of the 696 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. PRPH: -65.01 )
Ranked among companies with meaningful ROE (%) only.
PRPH' s 10-Year ROE (%) Range
Min: -67.21  Med: -9.85 Max: 97.9
Current: -65.01
-67.21
97.9
ROA (%) -42.33
PRPH's ROA (%) is ranked lower than
90% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.32 vs. PRPH: -42.33 )
Ranked among companies with meaningful ROA (%) only.
PRPH' s 10-Year ROA (%) Range
Min: -46.8  Med: -6.65 Max: 82.03
Current: -42.33
-46.8
82.03
ROC (Joel Greenblatt) (%) -132.89
PRPH's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.13 vs. PRPH: -132.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -145.68  Med: -27.55 Max: 443.04
Current: -132.89
-145.68
443.04
Revenue Growth (3Y)(%) 3.80
PRPH's Revenue Growth (3Y)(%) is ranked lower than
59% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. PRPH: 3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRPH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -32.5  Med: -2.40 Max: 125.9
Current: 3.8
-32.5
125.9
EBITDA Growth (3Y)(%) 41.20
PRPH's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 492 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. PRPH: 41.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRPH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -46.7  Med: -7.20 Max: 52.3
Current: 41.2
-46.7
52.3
EPS Growth (3Y)(%) 37.70
PRPH's EPS Growth (3Y)(%) is ranked higher than
86% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. PRPH: 37.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRPH' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.9  Med: 8.30 Max: 95.7
Current: 37.7
-41.9
95.7
» PRPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

PRPH Guru Trades in Q3 2014

Jim Simons 43,700 sh (+22.75%)
» More
Q4 2014

PRPH Guru Trades in Q4 2014

Jim Simons 47,700 sh (+9.15%)
» More
Q1 2015

PRPH Guru Trades in Q1 2015

Jim Simons 50,600 sh (+6.08%)
» More
Q2 2015

PRPH Guru Trades in Q2 2015

Jim Simons 61,200 sh (+20.95%)
» More
» Details

Insider Trades

Latest Guru Trades with PRPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.96
PRPH's P/B is ranked higher than
51% of the 644 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.12 vs. PRPH: 2.96 )
Ranked among companies with meaningful P/B only.
PRPH' s 10-Year P/B Range
Min: 0.87  Med: 2.48 Max: 7.44
Current: 2.96
0.87
7.44
P/S 1.12
PRPH's P/S is ranked higher than
79% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.13 vs. PRPH: 1.12 )
Ranked among companies with meaningful P/S only.
PRPH' s 10-Year P/S Range
Min: 0.61  Med: 1.40 Max: 4.46
Current: 1.12
0.61
4.46
Current Ratio 2.57
PRPH's Current Ratio is ranked higher than
56% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. PRPH: 2.57 )
Ranked among companies with meaningful Current Ratio only.
PRPH' s 10-Year Current Ratio Range
Min: 1.43  Med: 3.32 Max: 24.11
Current: 2.57
1.43
24.11
Quick Ratio 1.53
PRPH's Quick Ratio is ranked lower than
53% of the 617 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. PRPH: 1.53 )
Ranked among companies with meaningful Quick Ratio only.
PRPH' s 10-Year Quick Ratio Range
Min: 0.94  Med: 2.76 Max: 19.63
Current: 1.53
0.94
19.63
Days Inventory 159.99
PRPH's Days Inventory is ranked lower than
70% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.66 vs. PRPH: 159.99 )
Ranked among companies with meaningful Days Inventory only.
PRPH' s 10-Year Days Inventory Range
Min: 51.98  Med: 120.92 Max: 391.44
Current: 159.99
51.98
391.44
Days Sales Outstanding 20.51
PRPH's Days Sales Outstanding is ranked higher than
90% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.39 vs. PRPH: 20.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRPH' s 10-Year Days Sales Outstanding Range
Min: 51.96  Med: 77.56 Max: 273.75
Current: 20.51
51.96
273.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 151.00
PRPH's Price/Net Cash is ranked lower than
93% of the 178 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.02 vs. PRPH: 151.00 )
Ranked among companies with meaningful Price/Net Cash only.
PRPH' s 10-Year Price/Net Cash Range
Min: 1.38  Med: 9.55 Max: 380
Current: 151
1.38
380
Price/Net Current Asset Value 4.44
PRPH's Price/Net Current Asset Value is ranked higher than
70% of the 385 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. PRPH: 4.44 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PRPH' s 10-Year Price/Net Current Asset Value Range
Min: 0.47  Med: 3.87 Max: 12.88
Current: 4.44
0.47
12.88
Price/Tangible Book 2.96
PRPH's Price/Tangible Book is ranked higher than
57% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. PRPH: 2.96 )
Ranked among companies with meaningful Price/Tangible Book only.
PRPH' s 10-Year Price/Tangible Book Range
Min: 0.42  Med: 2.92 Max: 11.25
Current: 2.96
0.42
11.25
Price/Median PS Value 0.79
PRPH's Price/Median PS Value is ranked higher than
83% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.28 vs. PRPH: 0.79 )
Ranked among companies with meaningful Price/Median PS Value only.
PRPH' s 10-Year Price/Median PS Value Range
Min: 0.35  Med: 1.20 Max: 5.38
Current: 0.79
0.35
5.38
Earnings Yield (Greenblatt) (%) -33.86
PRPH's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. PRPH: -33.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRPH' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -33.86  Med: 0.90 Max: 3.1
Current: -33.86
-33.86
3.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
ProPhase Labs Inc is organized in Nevada in July 1989. The Company manufactures, markets and distributes homeopathic and health products that are offered to the general public. It also is engaged in the research and development of potential over-the-counter drug, natural base health products along with supplements, personal care and cosmeceutical products. It manufactures, distributes and markets over-the-counter cold remedy products to consumers through national chain, regional, specialty and local retail stores. Its flagship brand is Cold-EEZE Cold Remedy and its product is Cold-EEZE zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by 42%. In addition to Cold-EEZE Cold Remedy lozenges, the Company markets and distributes non-lozenge forms of zinc gluconate formulations: Cold-EEZE Cold Remedy QuickMelts and Cold-EEZE Cold Remedy Oral Spray. The Company expanded its Cold-EEZE Cold Remedy QuickMelts product line and shipped two products: Cold-EEZE Plus Immune Support QuickMelts and Cold-EEZE Plus Immune Support + Energy QuickMelts to retailers in July 2013. The company acquired manufacturing and distribution rights to its lozenge formulation in 1992 and commenced national marketing in 1996. The Company maintains trademarks for its products including Cold-EEZE, Kinds-EEZE, QuickMelts, Organix Rx Complete and Organix Rx Defense. The company is subject to federal and state laws and regulations adopted for the health and safety of users of pharmaceutical and health care products.
» More Articles for PRPH

Headlines

Articles On GuruFocus.com
ProPhase Labs, Inc. CEO & Chairman Ted William Karkus to Be Interviewed on Clear Channel - iHeart Bu Dec 11 2014 

More From Other Websites
PROPHASE LABS, INC. Financials Aug 25 2015
10-Q for ProPhase Labs, Inc. Aug 14 2015
ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2015 Aug 13 2015
PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 13 2015
PROPHASE LABS, INC. Files SEC form 10-Q, Quarterly Report Aug 12 2015
ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2015 Aug 12 2015
ProPhase Establishes 3.2 Million Share Equity Line Aug 11 2015
ProPhase Establishes 3.2 Million Share Equity Line Aug 05 2015
PROPHASE LABS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Aug 05 2015
PROPHASE LABS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 06 2015
PROPHASE LABS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders,... Jun 19 2015
PROPHASE LABS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 01 2015
Seasonal Businesses Sweat Year-Round To Shine On Time May 28 2015
PROPHASE LABS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... May 27 2015
PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 13 2015
PROPHASE LABS, INC. Files SEC form 10-Q, Quarterly Report May 13 2015
ProPhase Labs Reports Financial Results for the Three Months Ended March 31, 2015 May 13 2015
PROPHASE LABS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 17 2015
ProPhase Labs Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014 Apr 02 2015
PROPHASE LABS, INC. Files SEC form 10-K, Annual Report Mar 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK